OneBio Venture Studio Makes Second Investment Into Yemaachi Biotech
OneBio Venture Studio is proud to announce its second investment from Fund II into Yemaachi Biotech, a Ghana-based genomics company building the world’s most diverse cancer bio-database to develop next-generation cancer drugs that work across diverse populations. Yemaachi Biotech‘s work is rooted in a simple but powerful conviction: precision oncology research, diagnostics, and therapeutics must […]
2026 Pediatric Oncology Yvonne Award by OncoDaily
Emmanuella Amoako, MD, MWACP, FGCP, was honored with the Pediatric Oncology Yvonne Award during the Yvonne Awards Ceremony at OncoDaily Party 2026, held on May 29 at Park West in Chicago. Natera was the exclusive partner of the Yvonne Awards Ceremony and OncoDaily Reception. The recognition highlights Dr. Amoako’s work as a pediatric oncologist, clinical researcher, global health advocate, and leader in childhood […]
Biotech Bravado: What This Entrepreneur Is Pioneering In Africa – Forbes Africa.
At the laboratory of a genomics research company headquartered in Ghana’s capital Accra, the low, steady whir of a whole-genome sequencer, calibrated to read the most intimate instructions of human life, is helping process cancer samples collected thousands of miles away, from across Africa. “Sequencing is ongoing… We recruited over 300 people last year. So, […]
Yaw Bediako Recognized Among The 100 Most Influential CEOs in Oncology in 2025.
Yaw Bediako is an immunologist and the CEO of Yemaachi Biotech, an Accra-based immunogenomics company focused on diversifying precision oncology. Under his leadership, Yemaachi has positioned itself as a key contributor to African cancer research by leveraging the continent’s genetic diversity to identify novel biomarkers and therapeutic targets. A landmark achievement of his tenure is the 2025 launch […]
Dr. Yaw Bediako Joins Ashesi as Dean of Research and Innovation
Ashesi University is pleased to welcome Dr. Yaw Bediako as the Dean of Research and Innovation. In this role, he will provide strategic leadership to advance our research initiatives, foster innovation across various academic disciplines, and strengthen partnerships that support Ashesi’s mission. The Dean of Research and Innovation role highlights Ashesi’s commitment to deepening research […]
Bio Usawa and Yemaachi Biotech Unite to Transform HealthCare in Africa.
Diasporan biotech innovators co-develop monoclonal antibodies and genomic-driven solutions tailored for African patients. Kigali, Rwanda and Accra, Ghana — In a landmark collaboration, Bio Usawa, a pioneering biotechnology company building Africa’s monoclonal antibody development and manufacturing capacity, and Yemaachi Biotech, a leader in African cancer genomics, have joined forces to accelerate precision medicine and pharmacogenomics […]
Bloomberg New Economy Introduces the 2025 Class of Catalysts: Innovators Shaping a more Resilient, Inclusive Global Future.
Join our nine innovators, visionaries, scientists, and entrepreneurs — from Europe, Africa, Asia and North America — at this November’s Bloomberg New Economy Forum New York — October 20, 2025 — Bloomberg New Economy and Bloomberg Businessweek, today announced the 2025 Bloomberg New Economy Catalysts — a global community of entrepreneurs, scientists, policymakers, and visionaries driving transformative solutions […]
Building Biotechnology in Africa
At Yemaachi, Bediako is developing cancer diagnostics and treatments tailored to Africans, and he describes the limited official data on patients with cancer across Africa as a major challenge.
Precision Medicine on a Budget in Africa: using existing genetic data to mitigate adverse drug reactions to conventional cancer drugs.
Alexandra Lindsey Djomkam Zune , Charles Ochieng’ Olwal, Emmanuel Agbeli , Abdoulaye Baniré Diallo , Emmanuella Amoako, Yaw Bediako , Lily Paemka. Abstract Variations in drug-metabolizing enzymes and transporters are associated with adverse drug reactions (ADRs). ADRs to cancer drugs can differ among populations owing to environmental and genetic differences. Due to limited resources and prohibitive costs associated with drug development, African countries rely on […]